These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 20400651

  • 21. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole.
    Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivistö KT.
    Clin Pharmacol Ther; 2002 Oct; 72(4):362-9. PubMed ID: 12386638
    [Abstract] [Full Text] [Related]

  • 22. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
    Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK.
    Circulation; 2008 Jun 24; 117(25):3199-205. PubMed ID: 18559696
    [Abstract] [Full Text] [Related]

  • 23. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T, Kivistö KT, Backman JT, Neuvonen PJ.
    Clin Pharmacol Ther; 2000 Nov 24; 68(5):487-94. PubMed ID: 11103751
    [Abstract] [Full Text] [Related]

  • 24. New approaches to blockade of the renin-angiotensin-aldosterone system: characteristics and usefulness of the direct renin inhibitor aliskiren.
    Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Bokuda K, Itoh H.
    J Pharmacol Sci; 2010 Nov 24; 113(4):296-300. PubMed ID: 20675959
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren.
    Hong Y, Dingemanse J, Mager DE.
    Clin Pharmacol Ther; 2008 Jul 24; 84(1):136-43. PubMed ID: 18288088
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174.
    Kaukonen KM, Olkkola KT, Neuvonen PJ.
    Eur J Clin Pharmacol; 1998 Feb 24; 53(6):445-9. PubMed ID: 9551703
    [Abstract] [Full Text] [Related]

  • 29. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren.
    Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M.
    Pharmacogenet Genomics; 2013 Jan 24; 23(1):19-24. PubMed ID: 23151832
    [Abstract] [Full Text] [Related]

  • 30. Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects.
    Rebello S, Zhao S, Hariry S, Dahlke M, Alexander N, Vapurcuyan A, Hanna I, Jarugula V.
    Eur J Clin Pharmacol; 2012 May 24; 68(5):697-708. PubMed ID: 22124880
    [Abstract] [Full Text] [Related]

  • 31. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT.
    Clin Pharmacol Ther; 2005 Oct 24; 78(4):388-99. PubMed ID: 16198658
    [Abstract] [Full Text] [Related]

  • 32. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
    Vaidyanathan S, Valencia J, Kemp C, Zhao C, Yeh CM, Bizot MN, Denouel J, Dieterich HA, Dole WP.
    Int J Clin Pract; 2006 Nov 24; 60(11):1343-56. PubMed ID: 17073832
    [Abstract] [Full Text] [Related]

  • 33. Reversibility of the effects of aliskiren in the renal versus systemic circulation.
    Schneider MP, Janka R, Ziegler T, Raff U, Ritt M, Ott C, Veelken R, Uder M, Schmieder RE.
    Clin J Am Soc Nephrol; 2012 Feb 24; 7(2):258-64. PubMed ID: 22173856
    [Abstract] [Full Text] [Related]

  • 34. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment.
    Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP.
    J Clin Pharmacol; 2007 Feb 24; 47(2):192-200. PubMed ID: 17244770
    [Abstract] [Full Text] [Related]

  • 35. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole.
    Varis T, Kaukonen KM, Kivistö KT, Neuvonen PJ.
    Clin Pharmacol Ther; 1998 Oct 24; 64(4):363-8. PubMed ID: 9797792
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole).
    Kobayashi K, Abe Y, Kawai A, Furihata T, Endo T, Takeda H.
    J Clin Pharmacol; 2020 Oct 24; 60(10):1314-1323. PubMed ID: 32459872
    [Abstract] [Full Text] [Related]

  • 37. Aliskiren, the future of renin-angiotensin system blockade?
    Uresin Y, Mehtar Bozkurt M, Sabirli S, Ozunal ZG.
    Expert Rev Cardiovasc Ther; 2007 Sep 24; 5(5):835-49. PubMed ID: 17867914
    [Abstract] [Full Text] [Related]

  • 38. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects.
    Vaidyanathan S, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP.
    J Clin Pharmacol; 2007 Apr 24; 47(4):453-60. PubMed ID: 17389554
    [Abstract] [Full Text] [Related]

  • 39. Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.
    Sanoski CA.
    Pharmacotherapy; 2009 Feb 24; 29(2):193-212. PubMed ID: 19170589
    [Abstract] [Full Text] [Related]

  • 40. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects.
    Ayalasomayajula S, Yeh CM, Vaidyanathan S, Flannery B, Dieterich HA, Howard D, Bedigian MP, Dole WP.
    J Clin Pharmacol; 2008 Jul 24; 48(7):799-811. PubMed ID: 18490495
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.